Societal costs of obstructive sleep apnoea syndrome.

N Z Med J

Sleep/Wake Research Centre, Research School of Public Health, Massey University, Private Box 756 Wellington, New Zealand.

Published: August 2010

Aim: To estimate the societal costs of obstructive sleep apnoea syndrome (OSAS) in New Zealand and develop a simulation tool to evaluate treatment options.

Method: Treatment profiles, availability, uptake, and costs were based on services in the Wellington Region, and were used to develop a decision analytic model with micro costing of each potential outcome. Sensitivity analyses were conducted with 10,000 Monte Carlo simulations randomly varying each model parameter between high and low estimates.

Results: Total annual societal costs of OSAS for New Zealanders aged 30-60 years were estimated at $40 million (range $33-$90 million) or $419 per case, with accidents being the major contributor. This included 58% direct medical, 13% direct non-medical, 25% indirect, and 3% intangible costs. The estimated incremental net cost of treating OSAS was $389 per case treated (range $338-$427). The estimated incremental net direct medical cost per quality of life year (QALY) gained was $94 (range $56-$310).

Conclusion: The estimated incremental direct medical cost per QALY gained by OSAS treatment is well below the average QALY cost ($6865) for drugs selected by PHARMAC to receive government subsidy for use in the healthcare system. Thus, the analysis strongly supports the cost effectiveness of OSAS treatment.

Download full-text PDF

Source

Publication Analysis

Top Keywords

societal costs
12
direct medical
12
estimated incremental
12
costs obstructive
8
obstructive sleep
8
sleep apnoea
8
apnoea syndrome
8
incremental net
8
medical cost
8
qaly gained
8

Similar Publications

Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study.

J Neurol

January 2025

Department of Neurology, Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.

Background: Natalizumab (NAT) is an established disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, its use involves complex decision-making, often leading to initial use of lower efficacy therapies. Recently, the first biosimilar NAT was approved, enabling competitive pricing.

View Article and Find Full Text PDF

There is a large burden of stroke in the United States, and extensive systems of care have been established to address it. The resources devoted to stroke centers are analogous to those of trauma centers, both sharing many strict requirements for certification, clinical preparedness, quality improvement, data management, and reporting. However, trauma programs partly defray these costs through a trauma activation billing code, a billable fee that is charged for activation of the trauma team under strict criteria.

View Article and Find Full Text PDF

Previous studies suggest that NIPT's implementation differed widely across countries but offer limited insight into what shaped these differences. To address this gap, we conducted an in-depth analysis of how NIPT was incorporated into prenatal care in the US, the Netherlands, and Japan-countries with similar economic status-to identify actionable lessons. We conducted an integrative literature review on the process of introducing and implementing NIPT, stakeholders' roles, documented considerations in the decision to introduce NIPT, implementation choices, and NIPT uptake.

View Article and Find Full Text PDF

Costs of outpatient services at selected primary healthcare centers in Bangladesh: A cross-sectional study.

PLoS One

January 2025

Health Economics and Financing, Health Systems and Population Studies Division, icddr,b, Dhaka, Bangladesh.

Background: Upazila Health Complexes (UzHC) serve as the backbone of primary healthcare (PHC) at the sub-district level in Bangladesh, delivering comprehensive healthcare services including both inpatient and outpatient services to the grassroots levels. However, not all the prescribed medicines and diagnostics services are always available at these facilities for outpatient care. This results in out-of-pocket expenditure (OOPE) to the patients for getting prescribed medicines and diagnostics services which has not been properly explored.

View Article and Find Full Text PDF

Background: In Asian countries, discussing sex-related issues remains a taboo. Sexual dysfunction is not even considered a serious disorder in Pakistan.

Aim: To explore sexual dysfunction and marital satisfaction within the Pakistani context to develop supportive intervention programs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!